查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1140116

阿片类药物使用障碍市场：按药物类型、年龄组、给药途径、分销渠道：2021-2031 年全球机会分析和行业预测

Opioid Use Disorder Market By Drug Type, By Age group, By Route of Administration, By Distribution channal : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 324 Pages | 商品交期: 2-3个工作天内

价格

2021 年全球阿片类药物使用障碍市场价值为 1.962 亿美元，2022-2031 年的复合年增长率为 7.1%，到 2031 年将达到 3.858 亿美元。预计将达到美元。

阿片类药物是一种止痛药，含有放鬆肌肉、缓解疼痛和压力的物质。处方阿片类药物用于治疗中度至重度疼痛，包括氢可酮、羟考酮、可待因、芬太尼、美沙酮、吗啡和其他药物阿片类药物。阿片类药物使用障碍 (OUD) 是一种慢性和復发性脑部疾病，其特征是强迫性地寻求和使用阿片类药物，儘管有不良后果。阿片类药物使用障碍被认为是脑部疾病，因为它们涉及涉及动机、压力、自我调节和决策的大脑迴路的功能变化，这些变化在停止使用药物后仍会持续很长时间。阿片类药物使用障碍包括使用阿片类药物的强烈愿望、增加的阿片类药物耐受性和停药后的戒断综合征。

阿片类药物使用障碍市场是由越来越多患有各种严重慢性病的患者推动的，包括癌症、心血管疾病和外伤性疼痛。例如，根据世界癌症研究基金国际组织的数据，到 2020 年，全球将有大约 18,094,716 例新的癌症病例被诊断出来。乳腺癌和肺癌也是世界上最常见的癌症，有 2,261,419 例新髮乳腺癌病例和 2,206,771 例新发肺癌病例。因此，癌症患者数量的增加会增加手术的发生率。手术次数的增加会增加阿片类药物的使用以缓解术后疼痛。这些因素会导致阿片类药物成瘾。因此，预计这一因素将推动阿片类药物使用障碍市场的增长。此外，根据 JAMA Netw Open 期刊，2021 年 12 月，据报导约有 590 万人在 LAMEA 其他地区接受了外科手术。根据加拿大关节置换登记处 (CJRR) 的数据，2019-2020 年，加拿大进行了超过 75,000 例膝关节置换术和 63,000 例髋关节置换术。根据同一消息来源，膝关节和髋关节置换手术是加拿大第二常见的手术。该报告还预测，从 2019 年到 2020 年，髋关节置换手术将增加 2.4%。

此外，越来越多地考虑将丁丙诺啡贴片作为一种有效的治疗方式，推动了阿片类药物使用障碍市场的增长。越来越多地使用丁丙诺啡贴剂作为阿片类药物使用障碍的成功治疗方法是全球治疗阿片类药物成瘾市场的预期趋势之一。丁丙诺啡贴剂的使用被认为是治疗阿片类药物使用障碍的最先进策略。透皮贴剂是一种更舒适的给药方法，与註射等传统治疗方法相比，可提供更好的疼痛缓解，并允许患者自行给药。对于那些迫切需要治疗阿片类药物使用障碍的人来说，丁丙诺啡贴剂也可能是一种替代药物。此外，世界各国政府都在增加医疗保健支出。例如，根据医疗保险和医疗补助服务中心的数据，从 2020 年到 2019 年，美国的医疗保健支出将增长 9.7%，达到 4.1 万亿美元（每人 12,530 美元）。同样，根据英国国家统计局的数据，到 2020 年，英国的医疗保健总支出将占国内生产总值 (GDP) 的 12.8%，高于 2019 年的 10.2%。

此外，据估计，大约 30% 的医疗保健支出用于升级医疗保健基础设施，尤其是医院等公共卫生中心使用的医疗设备和药品。因此，预计全球医疗保健成本的增加将推动对治疗阿片类药物使用障碍药物应用的需求，推动阿片类药物使用障碍市场的增长。另一方面，与阿片类药物使用障碍药物相关的副作用预计将抑制阿片类药物使用障碍市场的增长。

内容

第一章介绍

第 2 章执行摘要

第 3 章市场概览

  • 市场定义和范围
  • 主要发现
    • 主要投资领域
  • 波特五力分析
  • 主要公司的定位
  • 市场动态
    • 驱动程序
    • 约束因素
    • 机会
  • COVID-19 影响分析

第 4 章阿片类药物使用障碍市场：按药物类型分类

  • 概览
    • 市场规模和预测
  • 激动剂
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类
    • 激动性阿片类药物使用障碍市场：按类型
      • 美沙酮市场规模和预测：按地区划分
      • 丁丙诺啡市场规模和预测：按地区划分
  • 拮抗剂
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类

第 5 章阿片类药物使用障碍市场：按年龄组划分

  • 概览
    • 市场规模和预测
  • 19 至 39 岁
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：国家/地区分析
  • 40-59
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类
  • 60 岁以上
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类

第 6 章。阿片类药物使用障碍市场：按给药途径

  • 概览
    • 市场规模和预测
  • 口语
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类
  • 静脉注射
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类
  • 舌下含片
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类

第 7 章。阿片类药物使用障碍市场：按分销渠道

  • 概览
    • 市场规模和预测
  • 医院药房
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类
  • 零售药房
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类

第 8 章。阿片类药物使用障碍市场：按地区划分

  • 概览
    • 市场规模和预测
  • 北美
    • 主要趋势和机遇
    • 北美市场规模和预测：按药物类型
      • 北美激动性阿片类药物使用障碍市场：按类型
    • 北美市场规模和预测：按年龄组划分
    • 北美市场规模和预测：按管理途径
    • 北美市场规模和预测：按分销渠道
    • 北美市场规模和预测：按国家/地区分类
      • 美国
      • 加拿大
      • 墨西哥
  • 欧洲
    • 主要趋势和机遇
    • 欧洲市场规模和预测：按药物类型
      • 欧洲激动性阿片类药物使用障碍市场：按类型
    • 欧洲市场规模和预测：按年龄组划分
    • 欧洲市场规模和预测：按管理途径
    • 欧洲市场规模和预测：按分销渠道
    • 欧洲市场规模和预测：按国家/地区分类
      • 德国
      • 法国
      • 英国
      • 意大利
      • 西班牙
      • 其他欧洲
  • 亚太地区
    • 主要趋势和机遇
    • 按药物类型划分的亚太市场规模和预测
      • 亚太地区激动剂阿片类药物使用障碍市场：按类型分类
    • 亚太地区市场规模和预测：按年龄组划分
    • 亚太地区的市场规模和预测（按管理途径）
    • 亚太地区市场规模和预测：按分销渠道
    • 亚太地区的市场规模和预测：按国家/地区分类
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
  • LAMEA
    • 主要趋势和机遇
    • LAMEA 市场规模和预测：按药物类型
      • LAMEA 激动性阿片类药物使用障碍市场：按类型
    • LAMEA 市场规模和预测：按年龄组划分
    • LAMEA 市场规模和预测：按管理途径
    • LAMEA 市场规模和预测：按分销渠道
    • LAMEA 市场规模和预测：按国家/地区分类
      • 巴西
      • 沙特阿拉伯
      • 南非
      • LAMEA 的其余部分

第 9 章商业条件

  • 简介
  • 关键成功策略
  • 10 家主要公司的产品映射
  • 竞赛仪表板
  • 比赛热图
  • 主要发展

第 10 章公司简介

  • Alkermes, Inc.
  • AstraZeneca plc
  • BioDelivery Sciences International Inc.,
  • braeburn pharmaceuticals
  • Camurus
  • Dr Reddy Laboratories Ltd
  • Pear Therapeutics
  • Hikma Pharmaceuticals PLC,
  • mallinckrodt pharmaceuticals
  • NYC Health Hospitals
  • Orexo AB
  • OREXO AB
  • Indivior PLC
  • Reckitt Benckiser Pharmaceuticals Inc
  • Sandoz
  • Titan Pharmaceuticals, Inc.
  • Viatris Inc
Product Code: A12303

The global opioid use disorder market was valued at $196.2 million in 2021, and is projected to reach $385.8 million by 2031, registering a CAGR of 7.1% from 2022 to 2031. Opioid is a class of pain relievers that includes substances, which relax muscles and alleviate pain & stress. Prescription opioids are used to treat moderate-to-severe pain such as hydrocodone, oxycodone, codeine, fentanyl, methadone, morphine, and other pharmaceutical opioids. Opioid usage disorder (OUD) is a chronic, relapsing brain disorder that is characterized by obsessive opioid seeking and use despite negative effects. Opioids use disorder is regarded as brain disorder because it involves functional alterations to brain circuits involved in motivation, stress, self-control, and decision-making, and those changes may persist for a long period after drug use has stopped. Opioid use disorder consists of an overpowering desire to use opioids, increased opioid tolerance, and withdrawal syndrome when discontinued.

The opioids use disorder market is driven by increase in number of patients suffering from wide range of severe and chronic diseases such as cancer, cardiovascular disease, pain arising from injuries and other conditions. For instance, according to World Cancer Research Fund International, in 2020, around 18,094,716 new cancer cases diagnosed over the globe. As per the same source Breast and lung cancers were the most common cancers worldwide, 2,261,419 breast cancer and 2,206,771 lung cancer new cases diagnosed over the globe. Thus, rise in number of cancer cases cause increase in incidence of surgeries. Surge in number of surgical procedures cause rise in use of opioid drugs to relieve post-surgical pain. Therefore, this factor can cause addiction of opioid drugs in patients. Thus, this factor is anticipated to drive the growth of opioids use disorder market. Moreover, according to the Journal of JAMA Netw Open, in December 2021, around 5. 9 million population were reported to have undergone surgical procedure in the Rest of LAMEA In addition, according to Canadian Joint Replacement Registry (CJRR), approximately more than 75,000 knee replacement and 63,000 hip replacement surgeries were performed in the Canada from 2019 to 2020. As per the same source the knee and hip replacement surgery is the second most common surgery in Canada. This report also states 2.4% increase in the hip replacement surgery from 2019 to 2020.

In addition, increase in consideration of buprenorphine patches as an effective treatment mode to propel opioids use disorder market growth. The increase in use of buprenorphine patches as a successful treatment for opioid use disorder is one of the anticipated trends in the global market for treating opioid addiction. The use of buprenorphine patches is regarded as a cutting-edge strategy for treating opioid use disorder. Transdermal patches are a more pleasant drug delivery method that successfully lowers pain and can be self-administered by the patient than conventional therapy modalities such as injections. These buprenorphine patches can also serve as a potential substitute for people who need immediate treatment for opioid use disorder. In addition, governments globally have increased the expenditure on the healthcare sector. For instance, according to the Centers for Medicare & Medicaid Services, the U.S. health care spending grew by 9.7% from 2020 to 2019, reaching $4.1 trillion ($12,530 per person). Similarly, as per the Office for National Statistics, total healthcare expenditure in the UK accounted for 12.8% of the gross domestic product (GDP) in 2020, compared to 10.2% in 2019.

Furthermore, it has been estimated that approximately 30% of the healthcare expenditure is used in upgrading the healthcare infrastructure, especially medical equipment and medicine used at public health centers, such as hospitals. Hence, the rise in healthcare expenditure across the globe is expected to fuel the demand for opioids use disorder drugs application for treatment purpose, thereby boosting the growth of opioid use disorder market. On the other hand, side effects associated to opioids use disorder drugs are anticipated to restrain the growth of the opioids use disorder market.

The opioids use disorder market is segmented on the basis of type, age group, route of administration, distribution channel, and region. On the basis of type, the market is segmented into agonist and antagonist. The agonist segment further sub-categorized into methadone and buprenorphine. On the basis of age group, the market is classified into 19 to 39, 40 to 59 and age 60 and over. On the basis of route of administration, the market is classified into oral, intravenous and sublingual. On the basis of distribution channel, the market is divided into hospital pharmacy, retail pharmacy. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Some of the major companies that operate in the global opioids use disorder market include Alkermes, AstraZeneca Plc., BioDelivery Sciences International Inc., Braeburn, Camurus, Cerebral, Dr Reddy, Hikma Pharmaceuticals PLC, Indivior PLC, Mallinckrodt Pharmaceuticals, NYC Health + Hospitals, Orexo AB, Pear Therapeutics, Pfizer, Reckitt Benckiser Pharmaceuticals Inc., Sandoz (Novartis), Titan Pharmaceuticals, Inc., and Viatris Inc.,

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the opioid use disorder market analysis from 2021 to 2031 to identify the prevailing opioid use disorder market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the opioid use disorder market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global opioid use disorder market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug Type

  • Agonist
    • Type
    • Methadone
    • Buprenorphine
  • Antagonist

By Age group

  • 19 to 39
  • 40 to 59
  • Age 60 and over

By Route of Administration

  • Oral
  • Intravenous
  • Sublingual

By Distribution channal

  • Hospital pharmacy
  • Retail Pharmacy

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • Alkermes, Inc.
    • AstraZeneca plc
    • BioDelivery Sciences International Inc.,
    • braeburn pharmaceuticals
    • Camurus
    • Dr Reddy Laboratories Ltd
    • Pear Therapeutics
    • Hikma Pharmaceuticals PLC,
    • mallinckrodt pharmaceuticals
    • NYC Health Hospitals
    • Orexo AB
    • OREXO AB
    • Indivior PLC
    • Reckitt Benckiser Pharmaceuticals Inc
    • Sandoz
    • Titan Pharmaceuticals, Inc.
    • Viatris Inc

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: OPIOID USE DISORDER MARKET, BY DRUG TYPE

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Agonist
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
    • 4.2.4 Agonist Opioid Use Disorder Market by Type
      • 4.2.4.1 Methadone Market size and forecast, by region
      • 4.2.4.2 Buprenorphine Market size and forecast, by region
  • 4.3 Antagonist
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country

CHAPTER 5: OPIOID USE DISORDER MARKET, BY AGE GROUP

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 19 to 39
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
  • 5.3 40 to 59
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country
  • 5.4 Age 60 and over
    • 5.4.1 Key market trends, growth factors and opportunities
    • 5.4.2 Market size and forecast, by region
    • 5.4.3 Market analysis by country

CHAPTER 6: OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Oral
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market analysis by country
  • 6.3 Intravenous
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market analysis by country
  • 6.4 Sublingual
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market analysis by country

CHAPTER 7: OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNAL

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 Hospital pharmacy
    • 7.2.1 Key market trends, growth factors and opportunities
    • 7.2.2 Market size and forecast, by region
    • 7.2.3 Market analysis by country
  • 7.3 Retail Pharmacy
    • 7.3.1 Key market trends, growth factors and opportunities
    • 7.3.2 Market size and forecast, by region
    • 7.3.3 Market analysis by country

CHAPTER 8: OPIOID USE DISORDER MARKET, BY REGION

  • 8.1 Overview
    • 8.1.1 Market size and forecast
  • 8.2 North America
    • 8.2.1 Key trends and opportunities
    • 8.2.2 North America Market size and forecast, by Drug Type
      • 8.2.2.1 North America Agonist Opioid Use Disorder Market by Type
    • 8.2.3 North America Market size and forecast, by Age group
    • 8.2.4 North America Market size and forecast, by Route of Administration
    • 8.2.5 North America Market size and forecast, by Distribution channal
    • 8.2.6 North America Market size and forecast, by country
      • 8.2.6.1 U.S.
      • 8.2.6.1.1 Market size and forecast, by Drug Type
      • 8.2.6.1.2 Market size and forecast, by Age group
      • 8.2.6.1.3 Market size and forecast, by Route of Administration
      • 8.2.6.1.4 Market size and forecast, by Distribution channal
      • 8.2.6.2 Canada
      • 8.2.6.2.1 Market size and forecast, by Drug Type
      • 8.2.6.2.2 Market size and forecast, by Age group
      • 8.2.6.2.3 Market size and forecast, by Route of Administration
      • 8.2.6.2.4 Market size and forecast, by Distribution channal
      • 8.2.6.3 Mexico
      • 8.2.6.3.1 Market size and forecast, by Drug Type
      • 8.2.6.3.2 Market size and forecast, by Age group
      • 8.2.6.3.3 Market size and forecast, by Route of Administration
      • 8.2.6.3.4 Market size and forecast, by Distribution channal
  • 8.3 Europe
    • 8.3.1 Key trends and opportunities
    • 8.3.2 Europe Market size and forecast, by Drug Type
      • 8.3.2.1 Europe Agonist Opioid Use Disorder Market by Type
    • 8.3.3 Europe Market size and forecast, by Age group
    • 8.3.4 Europe Market size and forecast, by Route of Administration
    • 8.3.5 Europe Market size and forecast, by Distribution channal
    • 8.3.6 Europe Market size and forecast, by country
      • 8.3.6.1 Germany
      • 8.3.6.1.1 Market size and forecast, by Drug Type
      • 8.3.6.1.2 Market size and forecast, by Age group
      • 8.3.6.1.3 Market size and forecast, by Route of Administration
      • 8.3.6.1.4 Market size and forecast, by Distribution channal
      • 8.3.6.2 France
      • 8.3.6.2.1 Market size and forecast, by Drug Type
      • 8.3.6.2.2 Market size and forecast, by Age group
      • 8.3.6.2.3 Market size and forecast, by Route of Administration
      • 8.3.6.2.4 Market size and forecast, by Distribution channal
      • 8.3.6.3 UK
      • 8.3.6.3.1 Market size and forecast, by Drug Type
      • 8.3.6.3.2 Market size and forecast, by Age group
      • 8.3.6.3.3 Market size and forecast, by Route of Administration
      • 8.3.6.3.4 Market size and forecast, by Distribution channal
      • 8.3.6.4 Italy
      • 8.3.6.4.1 Market size and forecast, by Drug Type
      • 8.3.6.4.2 Market size and forecast, by Age group
      • 8.3.6.4.3 Market size and forecast, by Route of Administration
      • 8.3.6.4.4 Market size and forecast, by Distribution channal
      • 8.3.6.5 Spain
      • 8.3.6.5.1 Market size and forecast, by Drug Type
      • 8.3.6.5.2 Market size and forecast, by Age group
      • 8.3.6.5.3 Market size and forecast, by Route of Administration
      • 8.3.6.5.4 Market size and forecast, by Distribution channal
      • 8.3.6.6 Rest of Europe
      • 8.3.6.6.1 Market size and forecast, by Drug Type
      • 8.3.6.6.2 Market size and forecast, by Age group
      • 8.3.6.6.3 Market size and forecast, by Route of Administration
      • 8.3.6.6.4 Market size and forecast, by Distribution channal
  • 8.4 Asia-Pacific
    • 8.4.1 Key trends and opportunities
    • 8.4.2 Asia-Pacific Market size and forecast, by Drug Type
      • 8.4.2.1 Asia-Pacific Agonist Opioid Use Disorder Market by Type
    • 8.4.3 Asia-Pacific Market size and forecast, by Age group
    • 8.4.4 Asia-Pacific Market size and forecast, by Route of Administration
    • 8.4.5 Asia-Pacific Market size and forecast, by Distribution channal
    • 8.4.6 Asia-Pacific Market size and forecast, by country
      • 8.4.6.1 China
      • 8.4.6.1.1 Market size and forecast, by Drug Type
      • 8.4.6.1.2 Market size and forecast, by Age group
      • 8.4.6.1.3 Market size and forecast, by Route of Administration
      • 8.4.6.1.4 Market size and forecast, by Distribution channal
      • 8.4.6.2 Japan
      • 8.4.6.2.1 Market size and forecast, by Drug Type
      • 8.4.6.2.2 Market size and forecast, by Age group
      • 8.4.6.2.3 Market size and forecast, by Route of Administration
      • 8.4.6.2.4 Market size and forecast, by Distribution channal
      • 8.4.6.3 India
      • 8.4.6.3.1 Market size and forecast, by Drug Type
      • 8.4.6.3.2 Market size and forecast, by Age group
      • 8.4.6.3.3 Market size and forecast, by Route of Administration
      • 8.4.6.3.4 Market size and forecast, by Distribution channal
      • 8.4.6.4 Australia
      • 8.4.6.4.1 Market size and forecast, by Drug Type
      • 8.4.6.4.2 Market size and forecast, by Age group
      • 8.4.6.4.3 Market size and forecast, by Route of Administration
      • 8.4.6.4.4 Market size and forecast, by Distribution channal
      • 8.4.6.5 South Korea
      • 8.4.6.5.1 Market size and forecast, by Drug Type
      • 8.4.6.5.2 Market size and forecast, by Age group
      • 8.4.6.5.3 Market size and forecast, by Route of Administration
      • 8.4.6.5.4 Market size and forecast, by Distribution channal
      • 8.4.6.6 Rest of Asia-Pacific
      • 8.4.6.6.1 Market size and forecast, by Drug Type
      • 8.4.6.6.2 Market size and forecast, by Age group
      • 8.4.6.6.3 Market size and forecast, by Route of Administration
      • 8.4.6.6.4 Market size and forecast, by Distribution channal
  • 8.5 LAMEA
    • 8.5.1 Key trends and opportunities
    • 8.5.2 LAMEA Market size and forecast, by Drug Type
      • 8.5.2.1 LAMEA Agonist Opioid Use Disorder Market by Type
    • 8.5.3 LAMEA Market size and forecast, by Age group
    • 8.5.4 LAMEA Market size and forecast, by Route of Administration
    • 8.5.5 LAMEA Market size and forecast, by Distribution channal
    • 8.5.6 LAMEA Market size and forecast, by country
      • 8.5.6.1 Brazil
      • 8.5.6.1.1 Market size and forecast, by Drug Type
      • 8.5.6.1.2 Market size and forecast, by Age group
      • 8.5.6.1.3 Market size and forecast, by Route of Administration
      • 8.5.6.1.4 Market size and forecast, by Distribution channal
      • 8.5.6.2 Saudi Arabia
      • 8.5.6.2.1 Market size and forecast, by Drug Type
      • 8.5.6.2.2 Market size and forecast, by Age group
      • 8.5.6.2.3 Market size and forecast, by Route of Administration
      • 8.5.6.2.4 Market size and forecast, by Distribution channal
      • 8.5.6.3 South Africa
      • 8.5.6.3.1 Market size and forecast, by Drug Type
      • 8.5.6.3.2 Market size and forecast, by Age group
      • 8.5.6.3.3 Market size and forecast, by Route of Administration
      • 8.5.6.3.4 Market size and forecast, by Distribution channal
      • 8.5.6.4 Rest of LAMEA
      • 8.5.6.4.1 Market size and forecast, by Drug Type
      • 8.5.6.4.2 Market size and forecast, by Age group
      • 8.5.6.4.3 Market size and forecast, by Route of Administration
      • 8.5.6.4.4 Market size and forecast, by Distribution channal

CHAPTER 9: COMPANY LANDSCAPE

  • 9.1. Introduction
  • 9.2. Top winning strategies
  • 9.3. Product Mapping of Top 10 Player
  • 9.4. Competitive Dashboard
  • 9.5. Competitive Heatmap
  • 9.6. Key developments

CHAPTER 10: COMPANY PROFILES

  • 10.1 Alkermes, Inc.
    • 10.1.1 Company overview
    • 10.1.2 Company snapshot
    • 10.1.3 Operating business segments
    • 10.1.4 Product portfolio
    • 10.1.5 Business performance
    • 10.1.6 Key strategic moves and developments
  • 10.2 AstraZeneca plc
    • 10.2.1 Company overview
    • 10.2.2 Company snapshot
    • 10.2.3 Operating business segments
    • 10.2.4 Product portfolio
    • 10.2.5 Business performance
    • 10.2.6 Key strategic moves and developments
  • 10.3 BioDelivery Sciences International Inc.,
    • 10.3.1 Company overview
    • 10.3.2 Company snapshot
    • 10.3.3 Operating business segments
    • 10.3.4 Product portfolio
    • 10.3.5 Business performance
    • 10.3.6 Key strategic moves and developments
  • 10.4 braeburn pharmaceuticals
    • 10.4.1 Company overview
    • 10.4.2 Company snapshot
    • 10.4.3 Operating business segments
    • 10.4.4 Product portfolio
    • 10.4.5 Business performance
    • 10.4.6 Key strategic moves and developments
  • 10.5 Camurus
    • 10.5.1 Company overview
    • 10.5.2 Company snapshot
    • 10.5.3 Operating business segments
    • 10.5.4 Product portfolio
    • 10.5.5 Business performance
    • 10.5.6 Key strategic moves and developments
  • 10.6 Dr Reddy Laboratories Ltd
    • 10.6.1 Company overview
    • 10.6.2 Company snapshot
    • 10.6.3 Operating business segments
    • 10.6.4 Product portfolio
    • 10.6.5 Business performance
    • 10.6.6 Key strategic moves and developments
  • 10.7 Pear Therapeutics
    • 10.7.1 Company overview
    • 10.7.2 Company snapshot
    • 10.7.3 Operating business segments
    • 10.7.4 Product portfolio
    • 10.7.5 Business performance
    • 10.7.6 Key strategic moves and developments
  • 10.8 Hikma Pharmaceuticals PLC,
    • 10.8.1 Company overview
    • 10.8.2 Company snapshot
    • 10.8.3 Operating business segments
    • 10.8.4 Product portfolio
    • 10.8.5 Business performance
    • 10.8.6 Key strategic moves and developments
  • 10.9 mallinckrodt pharmaceuticals
    • 10.9.1 Company overview
    • 10.9.2 Company snapshot
    • 10.9.3 Operating business segments
    • 10.9.4 Product portfolio
    • 10.9.5 Business performance
    • 10.9.6 Key strategic moves and developments
  • 10.10 NYC Health Hospitals
    • 10.10.1 Company overview
    • 10.10.2 Company snapshot
    • 10.10.3 Operating business segments
    • 10.10.4 Product portfolio
    • 10.10.5 Business performance
    • 10.10.6 Key strategic moves and developments
  • 10.11 Orexo AB
    • 10.11.1 Company overview
    • 10.11.2 Company snapshot
    • 10.11.3 Operating business segments
    • 10.11.4 Product portfolio
    • 10.11.5 Business performance
    • 10.11.6 Key strategic moves and developments
  • 10.12 OREXO AB
    • 10.12.1 Company overview
    • 10.12.2 Company snapshot
    • 10.12.3 Operating business segments
    • 10.12.4 Product portfolio
    • 10.12.5 Business performance
    • 10.12.6 Key strategic moves and developments
  • 10.13 Indivior PLC
    • 10.13.1 Company overview
    • 10.13.2 Company snapshot
    • 10.13.3 Operating business segments
    • 10.13.4 Product portfolio
    • 10.13.5 Business performance
    • 10.13.6 Key strategic moves and developments
  • 10.14 Reckitt Benckiser Pharmaceuticals Inc
    • 10.14.1 Company overview
    • 10.14.2 Company snapshot
    • 10.14.3 Operating business segments
    • 10.14.4 Product portfolio
    • 10.14.5 Business performance
    • 10.14.6 Key strategic moves and developments
  • 10.15 Sandoz
    • 10.15.1 Company overview
    • 10.15.2 Company snapshot
    • 10.15.3 Operating business segments
    • 10.15.4 Product portfolio
    • 10.15.5 Business performance
    • 10.15.6 Key strategic moves and developments
  • 10.16 Titan Pharmaceuticals, Inc.
    • 10.16.1 Company overview
    • 10.16.2 Company snapshot
    • 10.16.3 Operating business segments
    • 10.16.4 Product portfolio
    • 10.16.5 Business performance
    • 10.16.6 Key strategic moves and developments
  • 10.17 Viatris Inc
    • 10.17.1 Company overview
    • 10.17.2 Company snapshot
    • 10.17.3 Operating business segments
    • 10.17.4 Product portfolio
    • 10.17.5 Business performance
    • 10.17.6 Key strategic moves and developments

LIST OF TABLES

  • TABLE 1. GLOBAL OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 2. OPIOID USE DISORDER MARKET SIZE, FOR AGONIST, BY REGION, 2021-2031 ($MILLION)
  • TABLE 3. OPIOID USE DISORDER MARKET FOR AGONIST, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 4. GLOBAL AGONIST OPIOID USE DISORDER MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 5. OPIOID USE DISORDER MARKET, FOR METHADONE, BY REGION, 2021-2031 ($MILLION)
  • TABLE 6. OPIOID USE DISORDER MARKET, FOR BUPRENORPHINE, BY REGION, 2021-2031 ($MILLION)
  • TABLE 7. OPIOID USE DISORDER MARKET SIZE, FOR ANTAGONIST, BY REGION, 2021-2031 ($MILLION)
  • TABLE 8. OPIOID USE DISORDER MARKET FOR ANTAGONIST, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 9. GLOBAL OPIOID USE DISORDER MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 10. OPIOID USE DISORDER MARKET SIZE, FOR 19 TO 39, BY REGION, 2021-2031 ($MILLION)
  • TABLE 11. OPIOID USE DISORDER MARKET FOR 19 TO 39, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 12. OPIOID USE DISORDER MARKET SIZE, FOR 40 TO 59, BY REGION, 2021-2031 ($MILLION)
  • TABLE 13. OPIOID USE DISORDER MARKET FOR 40 TO 59, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 14. OPIOID USE DISORDER MARKET SIZE, FOR AGE 60 AND OVER, BY REGION, 2021-2031 ($MILLION)
  • TABLE 15. OPIOID USE DISORDER MARKET FOR AGE 60 AND OVER, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 16. GLOBAL OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 17. OPIOID USE DISORDER MARKET SIZE, FOR ORAL, BY REGION, 2021-2031 ($MILLION)
  • TABLE 18. OPIOID USE DISORDER MARKET FOR ORAL, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 19. OPIOID USE DISORDER MARKET SIZE, FOR INTRAVENOUS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 20. OPIOID USE DISORDER MARKET FOR INTRAVENOUS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 21. OPIOID USE DISORDER MARKET SIZE, FOR SUBLINGUAL, BY REGION, 2021-2031 ($MILLION)
  • TABLE 22. OPIOID USE DISORDER MARKET FOR SUBLINGUAL, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 23. GLOBAL OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNAL, 2021-2031 ($MILLION)
  • TABLE 24. OPIOID USE DISORDER MARKET SIZE, FOR HOSPITAL PHARMACY, BY REGION, 2021-2031 ($MILLION)
  • TABLE 25. OPIOID USE DISORDER MARKET FOR HOSPITAL PHARMACY, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 26. OPIOID USE DISORDER MARKET SIZE, FOR RETAIL PHARMACY, BY REGION, 2021-2031 ($MILLION)
  • TABLE 27. OPIOID USE DISORDER MARKET FOR RETAIL PHARMACY, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 28. OPIOID USE DISORDER MARKET, BY REGION, 2021-2031 ($MILLION)
  • TABLE 29. NORTH AMERICA OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 30. NORTH AMERICA AGONIST OPIOID USE DISORDER MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 31. NORTH AMERICA OPIOID USE DISORDER MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 32. NORTH AMERICA OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 33. NORTH AMERICA OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNAL, 2021-2031 ($MILLION)
  • TABLE 34. NORTH AMERICA OPIOID USE DISORDER MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 35. U.S. OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 36. U.S. OPIOID USE DISORDER MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 37. U.S. OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 38. U.S. OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNAL, 2021-2031 ($MILLION)
  • TABLE 39. CANADA OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 40. CANADA OPIOID USE DISORDER MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 41. CANADA OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 42. CANADA OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNAL, 2021-2031 ($MILLION)
  • TABLE 43. MEXICO OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 44. MEXICO OPIOID USE DISORDER MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 45. MEXICO OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 46. MEXICO OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNAL, 2021-2031 ($MILLION)
  • TABLE 47. EUROPE OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 48. EUROPE AGONIST OPIOID USE DISORDER MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 49. EUROPE OPIOID USE DISORDER MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 50. EUROPE OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 51. EUROPE OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNAL, 2021-2031 ($MILLION)
  • TABLE 52. EUROPE OPIOID USE DISORDER MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 53. GERMANY OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 54. GERMANY OPIOID USE DISORDER MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 55. GERMANY OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 56. GERMANY OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNAL, 2021-2031 ($MILLION)
  • TABLE 57. FRANCE OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 58. FRANCE OPIOID USE DISORDER MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 59. FRANCE OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 60. FRANCE OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNAL, 2021-2031 ($MILLION)
  • TABLE 61. UK OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 62. UK OPIOID USE DISORDER MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 63. UK OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 64. UK OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNAL, 2021-2031 ($MILLION)
  • TABLE 65. ITALY OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 66. ITALY OPIOID USE DISORDER MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 67. ITALY OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 68. ITALY OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNAL, 2021-2031 ($MILLION)
  • TABLE 69. SPAIN OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 70. SPAIN OPIOID USE DISORDER MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 71. SPAIN OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 72. SPAIN OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNAL, 2021-2031 ($MILLION)
  • TABLE 73. REST OF EUROPE OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 74. REST OF EUROPE OPIOID USE DISORDER MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 75. REST OF EUROPE OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 76. REST OF EUROPE OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNAL, 2021-2031 ($MILLION)
  • TABLE 77. ASIA-PACIFIC OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 78. ASIA-PACIFIC AGONIST OPIOID USE DISORDER MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 79. ASIA-PACIFIC OPIOID USE DISORDER MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 80. ASIA-PACIFIC OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 81. ASIA-PACIFIC OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNAL, 2021-2031 ($MILLION)
  • TABLE 82. ASIA-PACIFIC OPIOID USE DISORDER MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 83. CHINA OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 84. CHINA OPIOID USE DISORDER MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 85. CHINA OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 86. CHINA OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNAL, 2021-2031 ($MILLION)
  • TABLE 87. JAPAN OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 88. JAPAN OPIOID USE DISORDER MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 89. JAPAN OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 90. JAPAN OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNAL, 2021-2031 ($MILLION)
  • TABLE 91. INDIA OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 92. INDIA OPIOID USE DISORDER MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 93. INDIA OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 94. INDIA OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNAL, 2021-2031 ($MILLION)
  • TABLE 95. AUSTRALIA OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 96. AUSTRALIA OPIOID USE DISORDER MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 97. AUSTRALIA OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 98. AUSTRALIA OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNAL, 2021-2031 ($MILLION)
  • TABLE 99. SOUTH KOREA OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 100. SOUTH KOREA OPIOID USE DISORDER MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 101. SOUTH KOREA OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 102. SOUTH KOREA OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNAL, 2021-2031 ($MILLION)
  • TABLE 103. REST OF ASIA-PACIFIC OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 104. REST OF ASIA-PACIFIC OPIOID USE DISORDER MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 105. REST OF ASIA-PACIFIC OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 106. REST OF ASIA-PACIFIC OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNAL, 2021-2031 ($MILLION)
  • TABLE 107. LAMEA OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 108. LAMEA AGONIST OPIOID USE DISORDER MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 109. LAMEA OPIOID USE DISORDER MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 110. LAMEA OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 111. LAMEA OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNAL, 2021-2031 ($MILLION)
  • TABLE 112. LAMEA OPIOID USE DISORDER MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 113. BRAZIL OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 114. BRAZIL OPIOID USE DISORDER MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 115. BRAZIL OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 116. BRAZIL OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNAL, 2021-2031 ($MILLION)
  • TABLE 117. SAUDI ARABIA OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 118. SAUDI ARABIA OPIOID USE DISORDER MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 119. SAUDI ARABIA OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 120. SAUDI ARABIA OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNAL, 2021-2031 ($MILLION)
  • TABLE 121. SOUTH AFRICA OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 122. SOUTH AFRICA OPIOID USE DISORDER MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 123. SOUTH AFRICA OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 124. SOUTH AFRICA OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNAL, 2021-2031 ($MILLION)
  • TABLE 125. REST OF LAMEA OPIOID USE DISORDER MARKET, BY DRUG TYPE, 2021-2031 ($MILLION)
  • TABLE 126. REST OF LAMEA OPIOID USE DISORDER MARKET, BY AGE GROUP, 2021-2031 ($MILLION)
  • TABLE 127. REST OF LAMEA OPIOID USE DISORDER MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 128. REST OF LAMEA OPIOID USE DISORDER MARKET, BY DISTRIBUTION CHANNAL, 2021-2031 ($MILLION)
  • TABLE 129.ALKERMES, INC.: COMPANY SNAPSHOT
  • TABLE 130.ALKERMES, INC.: OPERATING SEGMENTS
  • TABLE 131.ALKERMES, INC.: PRODUCT PORTFOLIO
  • TABLE 132.ALKERMES, INC.: NET SALES,
  • TABLE 133.ALKERMES, INC.: KEY STRATERGIES
  • TABLE 134.ASTRAZENECA PLC: COMPANY SNAPSHOT
  • TABLE 135.ASTRAZENECA PLC: OPERATING SEGMENTS
  • TABLE 136.ASTRAZENECA PLC: PRODUCT PORTFOLIO
  • TABLE 137.ASTRAZENECA PLC: NET SALES,
  • TABLE 138.ASTRAZENECA PLC: KEY STRATERGIES
  • TABLE 139.BIODELIVERY SCIENCES INTERNATIONAL INC.,: COMPANY SNAPSHOT
  • TABLE 140.BIODELIVERY SCIENCES INTERNATIONAL INC.,: OPERATING SEGMENTS
  • TABLE 141.BIODELIVERY SCIENCES INTERNATIONAL INC.,: PRODUCT PORTFOLIO
  • TABLE 142.BIODELIVERY SCIENCES INTERNATIONAL INC.,: NET SALES,
  • TABLE 143.BIODELIVERY SCIENCES INTERNATIONAL INC.,: KEY STRATERGIES
  • TABLE 144.BRAEBURN PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 145.BRAEBURN PHARMACEUTICALS: OPERATING SEGMENTS
  • TABLE 146.BRAEBURN PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 147.BRAEBURN PHARMACEUTICALS: NET SALES,
  • TABLE 148.BRAEBURN PHARMACEUTICALS: KEY STRATERGIES
  • TABLE 149.CAMURUS: COMPANY SNAPSHOT
  • TABLE 150.CAMURUS: OPERATING SEGMENTS
  • TABLE 151.CAMURUS: PRODUCT PORTFOLIO
  • TABLE 152.CAMURUS: NET SALES,
  • TABLE 153.CAMURUS: KEY STRATERGIES
  • TABLE 154.DR REDDY LABORATORIES LTD: COMPANY SNAPSHOT
  • TABLE 155.DR REDDY LABORATORIES LTD: OPERATING SEGMENTS
  • TABLE 156.DR REDDY LABORATORIES LTD: PRODUCT PORTFOLIO
  • TABLE 157.DR REDDY LABORATORIES LTD: NET SALES,
  • TABLE 158.DR REDDY LABORATORIES LTD: KEY STRATERGIES
  • TABLE 159.PEAR THERAPEUTICS: COMPANY SNAPSHOT
  • TABLE 160.PEAR THERAPEUTICS: OPERATING SEGMENTS
  • TABLE 161.PEAR THERAPEUTICS: PRODUCT PORTFOLIO
  • TABLE 162.PEAR THERAPEUTICS: NET SALES,
  • TABLE 163.PEAR THERAPEUTICS: KEY STRATERGIES
  • TABLE 164.HIKMA PHARMACEUTICALS PLC,: COMPANY SNAPSHOT
  • TABLE 165.HIKMA PHARMACEUTICALS PLC,: OPERATING SEGMENTS
  • TABLE 166.HIKMA PHARMACEUTICALS PLC,: PRODUCT PORTFOLIO
  • TABLE 167.HIKMA PHARMACEUTICALS PLC,: NET SALES,
  • TABLE 168.HIKMA PHARMACEUTICALS PLC,: KEY STRATERGIES
  • TABLE 169.MALLINCKRODT PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 170.MALLINCKRODT PHARMACEUTICALS: OPERATING SEGMENTS
  • TABLE 171.MALLINCKRODT PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 172.MALLINCKRODT PHARMACEUTICALS: NET SALES,
  • TABLE 173.MALLINCKRODT PHARMACEUTICALS: KEY STRATERGIES
  • TABLE 174.NYC HEALTH HOSPITALS: COMPANY SNAPSHOT
  • TABLE 175.NYC HEALTH HOSPITALS: OPERATING SEGMENTS
  • TABLE 176.NYC HEALTH HOSPITALS: PRODUCT PORTFOLIO
  • TABLE 177.NYC HEALTH HOSPITALS: NET SALES,
  • TABLE 178.NYC HEALTH HOSPITALS: KEY STRATERGIES
  • TABLE 179.OREXO AB: COMPANY SNAPSHOT
  • TABLE 180.OREXO AB: OPERATING SEGMENTS
  • TABLE 181.OREXO AB: PRODUCT PORTFOLIO
  • TABLE 182.OREXO AB: NET SALES,
  • TABLE 183.OREXO AB: KEY STRATERGIES
  • TABLE 184.OREXO AB: COMPANY SNAPSHOT
  • TABLE 185.OREXO AB: OPERATING SEGMENTS
  • TABLE 186.OREXO AB: PRODUCT PORTFOLIO
  • TABLE 187.OREXO AB: NET SALES,
  • TABLE 188.OREXO AB: KEY STRATERGIES
  • TABLE 189.INDIVIOR PLC: COMPANY SNAPSHOT
  • TABLE 190.INDIVIOR PLC: OPERATING SEGMENTS
  • TABLE 191.INDIVIOR PLC: PRODUCT PORTFOLIO
  • TABLE 192.INDIVIOR PLC: NET SALES,
  • TABLE 193.INDIVIOR PLC: KEY STRATERGIES
  • TABLE 194.RECKITT BENCKISER PHARMACEUTICALS INC: COMPANY SNAPSHOT
  • TABLE 195.RECKITT BENCKISER PHARMACEUTICALS INC: OPERATING SEGMENTS
  • TABLE 196.RECKITT BENCKISER PHARMACEUTICALS INC: PRODUCT PORTFOLIO
  • TABLE 197.RECKITT BENCKISER PHARMACEUTICALS INC: NET SALES,
  • TABLE 198.RECKITT BENCKISER PHARMACEUTICALS INC: KEY STRATERGIES
  • TABLE 199.SANDOZ: COMPANY SNAPSHOT
  • TABLE 200.SANDOZ: OPERATING SEGMENTS
  • TABLE 201.SANDOZ: PRODUCT PORTFOLIO
  • TABLE 202.SANDOZ: NET SALES,
  • TABLE 203.SANDOZ: KEY STRATERGIES
  • TABLE 204.TITAN PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
  • TABLE 205.TITAN PHARMACEUTICALS, INC.: OPERATING SEGMENTS
  • TABLE 206.TITAN PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
  • TABLE 207.TITAN PHARMACEUTICALS, INC.: NET SALES,
  • TABLE 208.TITAN PHARMACEUTICALS, INC.: KEY STRATERGIES
  • TABLE 209.VIATRIS INC: COMPANY SNAPSHOT
  • TABLE 210.VIATRIS INC: OPERATING SEGMENTS
  • TABLE 211.VIATRIS INC: PRODUCT PORTFOLIO
  • TABLE 212.VIATRIS INC: NET SALES,
  • TABLE 213.VIATRIS INC: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.OPIOID USE DISORDER MARKET SEGMENTATION
  • FIGURE 2.OPIOID USE DISORDER MARKET,2021-2031
  • FIGURE 3.OPIOID USE DISORDER MARKET,2021-2031
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.OPIOID USE DISORDER MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.OPIOID USE DISORDER MARKET,BY DRUG TYPE,2021(%)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF AGONIST OPIOID USE DISORDER MARKET,2021-2031(%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF ANTAGONIST OPIOID USE DISORDER MARKET,2021-2031(%)
  • FIGURE 15.OPIOID USE DISORDER MARKET,BY AGE GROUP,2021(%)
  • FIGURE 16.COMPARATIVE SHARE ANALYSIS OF 19 TO 39 OPIOID USE DISORDER MARKET,2021-2031(%)
  • FIGURE 17.COMPARATIVE SHARE ANALYSIS OF 40 TO 59 OPIOID USE DISORDER MARKET,2021-2031(%)
  • FIGURE 18.COMPARATIVE SHARE ANALYSIS OF AGE 60 AND OVER OPIOID USE DISORDER MARKET,2021-2031(%)
  • FIGURE 19.OPIOID USE DISORDER MARKET,BY ROUTE OF ADMINISTRATION,2021(%)
  • FIGURE 20.COMPARATIVE SHARE ANALYSIS OF ORAL OPIOID USE DISORDER MARKET,2021-2031(%)
  • FIGURE 21.COMPARATIVE SHARE ANALYSIS OF INTRAVENOUS OPIOID USE DISORDER MARKET,2021-2031(%)
  • FIGURE 22.COMPARATIVE SHARE ANALYSIS OF SUBLINGUAL OPIOID USE DISORDER MARKET,2021-2031(%)
  • FIGURE 23.OPIOID USE DISORDER MARKET,BY DISTRIBUTION CHANNAL,2021(%)
  • FIGURE 24.COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACY OPIOID USE DISORDER MARKET,2021-2031(%)
  • FIGURE 25.COMPARATIVE SHARE ANALYSIS OF RETAIL PHARMACY OPIOID USE DISORDER MARKET,2021-2031(%)
  • FIGURE 26.OPIOID USE DISORDER MARKET BY REGION,2021
  • FIGURE 27.U.S. OPIOID USE DISORDER MARKET,2021-2031($MILLION)
  • FIGURE 28.CANADA OPIOID USE DISORDER MARKET,2021-2031($MILLION)
  • FIGURE 29.MEXICO OPIOID USE DISORDER MARKET,2021-2031($MILLION)
  • FIGURE 30.GERMANY OPIOID USE DISORDER MARKET,2021-2031($MILLION)
  • FIGURE 31.FRANCE OPIOID USE DISORDER MARKET,2021-2031($MILLION)
  • FIGURE 32.UK OPIOID USE DISORDER MARKET,2021-2031($MILLION)
  • FIGURE 33.ITALY OPIOID USE DISORDER MARKET,2021-2031($MILLION)
  • FIGURE 34.SPAIN OPIOID USE DISORDER MARKET,2021-2031($MILLION)
  • FIGURE 35.REST OF EUROPE OPIOID USE DISORDER MARKET,2021-2031($MILLION)
  • FIGURE 36.CHINA OPIOID USE DISORDER MARKET,2021-2031($MILLION)
  • FIGURE 37.JAPAN OPIOID USE DISORDER MARKET,2021-2031($MILLION)
  • FIGURE 38.INDIA OPIOID USE DISORDER MARKET,2021-2031($MILLION)
  • FIGURE 39.AUSTRALIA OPIOID USE DISORDER MARKET,2021-2031($MILLION)
  • FIGURE 40.SOUTH KOREA OPIOID USE DISORDER MARKET,2021-2031($MILLION)
  • FIGURE 41.REST OF ASIA-PACIFIC OPIOID USE DISORDER MARKET,2021-2031($MILLION)
  • FIGURE 42.BRAZIL OPIOID USE DISORDER MARKET,2021-2031($MILLION)
  • FIGURE 43.SAUDI ARABIA OPIOID USE DISORDER MARKET,2021-2031($MILLION)
  • FIGURE 44.SOUTH AFRICA OPIOID USE DISORDER MARKET,2021-2031($MILLION)
  • FIGURE 45.REST OF LAMEA OPIOID USE DISORDER MARKET,2021-2031($MILLION)
  • FIGURE 46. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 47. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 48. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 49.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 50.COMPETITIVE DASHBOARD
  • FIGURE 51.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 52.ALKERMES, INC..: NET SALES ,($MILLION)
  • FIGURE 53.ASTRAZENECA PLC.: NET SALES ,($MILLION)
  • FIGURE 54.BIODELIVERY SCIENCES INTERNATIONAL INC.,.: NET SALES ,($MILLION)
  • FIGURE 55.BRAEBURN PHARMACEUTICALS.: NET SALES ,($MILLION)
  • FIGURE 56.CAMURUS.: NET SALES ,($MILLION)
  • FIGURE 57.DR REDDY LABORATORIES LTD.: NET SALES ,($MILLION)
  • FIGURE 58.PEAR THERAPEUTICS.: NET SALES ,($MILLION)
  • FIGURE 59.HIKMA PHARMACEUTICALS PLC,.: NET SALES ,($MILLION)
  • FIGURE 60.MALLINCKRODT PHARMACEUTICALS.: NET SALES ,($MILLION)
  • FIGURE 61.NYC HEALTH HOSPITALS.: NET SALES ,($MILLION)
  • FIGURE 62.OREXO AB.: NET SALES ,($MILLION)
  • FIGURE 63.OREXO AB.: NET SALES ,($MILLION)
  • FIGURE 64.INDIVIOR PLC.: NET SALES ,($MILLION)
  • FIGURE 65.RECKITT BENCKISER PHARMACEUTICALS INC.: NET SALES ,($MILLION)
  • FIGURE 66.SANDOZ.: NET SALES ,($MILLION)
  • FIGURE 67.TITAN PHARMACEUTICALS, INC..: NET SALES ,($MILLION)
  • FIGURE 68.VIATRIS INC.: NET SALES ,($MILLION)